000			namba22 7a 4500
999			_c17702 _d17702
003			PC17702
005			20231019125429.0
008			231019b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_91432 _aGarcía Hernández, Gloria _ePediatría
245	0	0	_aConsenso para el abordaje del asma grave pediátrica en la práctica clínica habitual . _h[artículo]
260			_bAnales de pediatría (Barcelona, Spain:2003), _c2016
300			_a122.e1-122.e11.
500			_aFormato Vancouver: Plaza AM, Ibáñez MD, Sánchez Solís M, Bosque García M, Cabero MJ, Corzo JL et al. Consenso para el abordaje del asma grave pediátrica en la práctica clínica habitual . An Pediatr (Barc). 2016 Feb;84(2):122.e1-122.e11.
501			_aPMID: 26515042
504			_aContiene 31 referencias
520			_aIntroduction: Accurate identification of paediatric patients with severe asthma is essential for an adequate management of the disease. However, criteria for defining severe asthma and recommendations for control vary among different guidelines. Material and methods: An online survey was conducted to explore expert opinions about the definition and management of severe paediatric asthma. To reach a consensus agreement, a modified Delphi technique was used, and practice guidelines were prepared after the analysis of the results. Results: Eleven paediatric chest disease physicians and allergy specialists with wide expertise in severe asthma responded to the survey. Consensus was reached in 50 out of 65 questions (76.92%). It was considered that a patient has severe asthma if during the previous year they have required 2 or more cycles of oral steroids, required daily treatment with medium doses of inhaled corticosteroids (with other controller medication) or high doses (with or without other controller medication), did not respond to optimised conventional treatment, or if the disease threatened the life of the patient or seriously impairs their quality of life. The definition of severe asthma may also include patients who justifiably use health resources on a regular basis, or have psychosocial or environmental factors impeding control. For monitoring, the use of questionnaires designed specifically for paediatric population, such as CAN or ACT, is recommended. As regards treatment, the use of omalizumab should be considered prior to the use of oral corticosteroids. Conclusions: This paper provides consensus recommendations that may be useful in the management of severe paediatric asthma.
710			_9446 _aServicio de Pediatría-Neonatología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17702.pdf _ySolicitar documento
942			_2ddc _cART _n0